Cronin et al. conducted an analysis of over 100 samples at different stages of progression and demonstrated a progressive and significant increase in EGFR expression along the metaplasia–dysplasia–adenocarcinoma sequence, with overexpression detected in 35% of high-grade dysplasia (HGD) cases and 80% of adenocarcinomas. Here, EGFR is linked to dysplasia.